|
|
Prepublished online as a Blood First Edition Paper on July 18, 2002; DOI 10.1182/blood-2002-05-1358.
Submitted May 9, 2002
Accepted July 5, 2002
Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells
Richard L Darley*, Lorna Pearn, Nader Omidvar, Marion Sweeney, Janet Fisher, Sarah Phillips, Terry Hoy, and Alan K Burnett
Haematology, UWCM, Cardiff, United Kingdom
* Corresponding author; email: darley{at}cf.ac.uk.
RAS mutations are one of the most frequent molecular abnormalities associated with myeloid leukaemia and preleukaemia, yet there is a poor understanding of how they contribute to the pathogenesis of these conditions. Here, we describe the consequences of ectopic mutant N-Ras (N-Ras*) expression on normal human erythropoiesis. We show that during early (EPO-independent) erythropoiesis, N-Ras* promoted the amplification of a phenotypically primitive but functionally defective sub-population of CD34+ erythroblasts. N-Ras* also up-regulated the expression of megakaryocyte antigens on human erythroblasts. Though early erythroblasts expressing N-Ras* were able to respond to erythropoietin and generate mature progeny, this occurred with greatly reduced efficiency, probably explaining the poor colony growth characteristics of these cells. We further report that this oncogene promoted the expression and activation of protein kinase C (PKC) and that the effects of N-Ras* on erythropoiesis could be abrogated or attenuated by inhibition of PKC. Similarly, the effects of this oncogene could be partially mimicked by treatment with PKC agonist. Together, these data suggest that expression of N-Ras* is able to subvert the normal developmental cues which regulate erythropoiesis by activating PKC. This gives rise to phenotypic and functional abnormalities commonly observed in preleukaemia, suggesting a direct link between RAS mutations and the pathogenesis of preleukaemia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. G. Besteman, K. L. Zimmerman, W. R. Huckle, M. R. Prater, R. M. Gogal Jr., and S. D. Holladay
2,3,7,8-Tetrachlorodibenzo-P-Dioxin (TCDD) or Diethylstilbestrol (DES) Cause Similar Hematopoietic Hypocellularity and Hepatocellular Changes in Murine Fetal Liver, but Differentially Affect Gene Expression
Toxicol Pathol,
October 1, 2007;
35(6):
786 - 792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Pearn, J. Fisher, A. K. Burnett, and R. L. Darley
The role of PKC and PDK1 in monocyte lineage specification by Ras
Blood,
May 15, 2007;
109(10):
4461 - 4469.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Omidvar, L. Pearn, A. K. Burnett, and R. L. Darley
Ral Is both Necessary and Sufficient for the Inhibition of Myeloid Differentiation Mediated by Ras
Mol. Cell. Biol.,
May 15, 2006;
26(10):
3966 - 3975.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Zhang and H. F. Lodish
Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors
Blood,
September 15, 2004;
104(6):
1679 - 1687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Braun, D. A. Tuveson, N. Kong, D. T. Le, S. C. Kogan, J. Rozmus, M. M. Le Beau, T. E. Jacks, and K. M. Shannon
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder
PNAS,
January 13, 2004;
101(2):
597 - 602.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
